GMED
Spine and trauma are carrying the backpack
Globus Medical’s latest quarter looked a lot like a team project where two people did the work and the others quietly stared at the spreadsheet. Revenue hit $789.6 million in Q2 2026, up 6% from a year earlier, thanks mainly to strength in spine and trauma.
The not-so-fun part
Not everything was sparkling. The company said enabling technologies and Nevro were weaker, which matters because investors love a clean growth story almost as much as dentists love floss. When some parts of the business hum and others wobble, the market starts asking whether momentum is broad-based or just a couple of hot engines.
Why investors should care
For healthcare investors, this is the difference between “nice quarter” and “show me the sequel.”
- Strong spine and trauma sales suggest core demand is still healthy
- Weakness in other segments keeps the margin-and-mix conversation alive
- The stock can move if investors decide the growth is durable instead of one-quarter-only sparkle
Big picture: Globus is still very much in the fight, but the next few quarters will need to prove this wasn’t just a good lap around the track.